MIC测量通过微量稀释稀释法进行，使用RPIMI 1640培养基，用0.165M MOPS和10N NaOH调节至pH7.0。
适应症
念珠菌和隐球菌感染
真菌性菌血症，呼吸道真菌病，肠道真菌病，尿路感染，真菌性脑膜炎
预防造血干细胞移植患者的深部真菌病
用法与用量
成人
念珠菌病：通常成人每天静脉注射氟康唑50至100毫克。
隐球菌病：通常成人每天静脉注射50至200毫克氟康唑。
在严重或难治性真菌感染的情况下，可以将其作为每日剂量增加至400mg。
预防造血干细胞移植患者的深部真菌病：对于成人，每天静脉注射400毫克氟康唑。
婴儿
念珠菌病：通常，婴儿每天静脉注射3毫克/千克，作为儿童氟康唑。
隐球菌病：通常，婴儿每天一次静脉注射3至6mg/kg氟康唑。
在严重或难治性真菌感染的情况下，每日剂量可增加至12mg/kg。
在造血干细胞移植患者中预防深部真菌病：在儿童中，每天一次静脉注射12mg/kg作为氟康唑。
应注意，根据患者的状况适当减少剂量。
但是，每日剂量不应超过400毫克。
新生儿
对于14日龄以下的新生儿，每72小时给孩子服用与氟康唑相同的剂量。
对于15日龄后的新生儿，氟康唑以与儿童相同的剂量给药48小时。
临床结果
1.临床效果
（1）念珠菌病，隐球菌病
在开发时的临床试验中，将氟康唑静脉内施用于各种深部真菌病，并获得了优异的临床效果。
（2）预防（国外临床试验）
在一项随机，双盲，对照临床用于骨髓移植患者357试验中，在基团氟康唑预防不成功注给药（胶囊或静脉内溶液）一次口服或静脉内每日400毫克如）实施例105/179例（58.7％），安慰剂治疗组预防失败病例为123/177例（69.5％）。
注意：预防性失败不成功：全身感染（已证实）和疑似疑似全身性感染被认为是不成功的预防性给药。
2.真菌学效应
念珠菌属，C.albicans83.3％（10/12），在C.parapsilosis100％，C.tropicalis75.0％（3/4），其他78.6％（11/14），念珠菌总失踪率为82.9％（29/35）。
在新型隐球菌3株中，有2株减少菌株和1株不变菌株。
包装
静脉注射液
50mg：5个小瓶
100mg：5个小瓶
200mg：5个小瓶
制造销售
辉瑞公司
注：以上中文处方资料不够完整，使用者以原处方资料为准。
完整说明书附件：http://www.info.pmda.go.jp/go/pack/6290401A1099_2_12/
Diflucan Intravenous Solution（fluconazole）
Diflucan intravenous solution 50mg:
5vials Diflucan intravenous solution 100mg:
5 vials Diflucan intravenous solution 200mg:
5 vials
* For the diflucan capsule 50mg/100mg and the diflucan intravenous solution 50 mg/100mg/200mg, in addition to the addition of the indication and effect of "prevention of deep fungal diseases in hematopoietic stem cell transplant patients" in November last year and the "dosage regimen for children" We have obtained additional approval of.
Fluconazole (Diflucan)
Fluconazole (Diflucan) is an approved anti-fungal drug. It works by inhibiting the synthesis of ergosterol, a main component in the fungal cell membrane.
Fluconazole is manufactured by Pfizer, but alternative generic versions are available in some countries. Fluconazole is available in capsules, a liquid for intravenous infusion or a solution to be drunk.
Fluconazole is licensed for treating candidiasis and cryptococcal meningitis, and for preventing recurrences of cryptococcal meningitis after treatment.1 It is also active in HIV-positive adults and children.
Fluconazole is also being tested as a treatment or prophylaxis for other fungal diseases such as aspergillosis, coccidioidomycosis and histoplasmosis.
Resistance to fluconazole can occur, particularly in people with more advanced HIV infection. In these cases, alternative anti-fungal drugs such as itraconazole (Sporanox) or ketoconazole (Nizoral) may be used.
People who are starting fluconazole treatment for candidiasis or meningitis are usually recommended to start with a higher loading dose of 400mg daily before reducing the dose to the standard 200mg daily.
The dose of fluconazole should be reduced in people who have kidney impairment.
Fluconazole’s commonest side-effect is upset stomach. In rare cases, it can also cause clinically important, even fatal liver inflammation.
Skin rashes have also been reported, primarily in people taking fluconazole at the same time as several other drugs. Other occasional side-effects include nausea and vomiting, headache, seizures, Stevens-Johnson syndrome and hair loss.
Fluconazole causes an approximate doubling of nevirapine (Viramune) levels, increasing the risk of liver toxicity. Nevirapine does not affect fluconazole levels.7 Fluconazole also increases the blood levels of tipranavir (Aptivus).8 Does of more than 200mg fluconazole are not recommended in patients taking tipranavir.
